In vitro antimicrobial resistance properties of rifapentine and rifampicin are indistinguishable
Abstract
Tuberculosis (TB) is a major global health threat, with millions of new cases diagnosed annually. Rifampicin is a cornerstone drug in the current standard of care for TB treatment. Recently, rifapentine, an analog of rifampicin, has been considered as an alternative to rifampicin primarily due to its longer half-life and shorter 4-month TB treatment regimens. Despite some encouraging advantages in the clinical setting, the rifamycin resistance mutation frequency and type have yet to be systematically investigated. The mutation identity and frequency could directly impact clinical outcomes and the epidemiology of TB resistance. Our objective was to compare the in vitro antimicrobial properties of rifapentine and rifampicin across four Mycobacterium tuberculosis strains, namely H37Rv, CDC1551, HN878, and W4, a lineage 2 (Beijing) genotype, and to determine whether resistance differed between the two drugs. We compared the frequency of resistance between rifampicin and rifapentine at various concentrations, and evaluated the frequency of different mutation types in the four chosen TB strains via Sanger sequencing. Overall, no significant differences were observed in the frequency of resistance or mutation identity between rifampicin and rifapentine; however, strain-dependent differences were noted. H37Rv showed a higher frequency of resistance at all concentrations tested in both drugs compared to CDC1551 and the Beijing strains W4 and HN878. The profound overlap in in vitro…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.